BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

Ovarian cancer clinical trials and catalysts

Active industry-sponsored trials on ClinicalTrials.gov for ovarian cancer: 389 (240 sponsors; 57 newly posted in the last 180 days, 25 stopped in the last 180 days; 29 new-entrant sponsors). Momentum score 11.6, rank 60 of 91 on the disease-area ranking. As of 2026-11-18.

Phase distribution: Early Phase 1 2, Phase 1 130, Phase 2 156, Phase 3 62, Phase 4 2, N/A 37.

Most active sponsors, by phase

SponsorActive trialsBy phaseNew (window)Upcoming readouts
AstraZeneca AZN25P2 11, P3 8, NA 3, P1 322
Merck Sharp & Dohme LLC MRK7P3 5, P2 1, P1 130
Genmab GMAB6P3 5, P2 120
Daiichi Sankyo6P3 3, P1 1, P2 211
GlaxoSmithKline6P3 3, P4 1, P1 1, P2 121
Incyte Corporation INCY4P3 2, P2 1, P1 111
Hansoh BioMedical R&D Company3P3 2, P2 111
Sichuan Baili Pharmaceutical Co., Ltd.3P3 2, P2 101
Suzhou Suncadia Biopharmaceuticals Co., Ltd.3P3 2, P2 111
Tesaro, Inc.2P3 200
Tolmar Inc.2P3 201
AbbVie ABBV16P1 5, P2 6, NA 4, P3 133
Eli Lilly and Company LLY9P1 6, P3 1, P2 213
CanariaBio Inc.4P2 3, P3 103
Verastem, Inc. VSTM4P2 3, P3 110
EMD Serono Research & Development Institute, Inc.3P1 2, P3 102
Imunon IMNN3P3 1, P2 200
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc3P1 1, P3 1, P2 101
Qilu Pharmaceutical Co., Ltd.3P3 1, P2 221
BeiGene2P3 1, P1 100
Corcept Therapeutics CORT2P2 1, P3 100
CSPC Megalith Biopharmaceutical Co.,Ltd. new entrant2P2 1, P3 120
Innovent Biologics (Suzhou) Co. Ltd.2P3 1, P2 100
Pfizer PFE2P2 1, P3 102
Amgen AMGN1P3 100

New-entrant sponsors: CSPC Megalith Biopharmaceutical Co.,Ltd..

Recently stopped trials

Upcoming trial readouts (next 90 days)

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-30 est.P2/P3CAS Lamvac (Guangzhou) Biomedical Technology Co., Ltd.NCT05924776 Plasmodium Immunotherapy for Advanced Ovarian CancerAdvanced Ovarian Cancernot yet recruiting30
2026-12 est.P3Genelux Corporation GNLXNCT05281471 Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/RefractoryPlatinum-resistant Ovarian Cancer; Platinum-refractory Ovarian Cancer; Fallopian Tube Cancer; Primarrecruiting186
2026-12 est.P1/P2858 Therapeutics, Inc.NCT06395519 A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid MalignanciesAdvanced or Metastatic Solid Tumors; Breast Cancer; Ovarian Cancer; Prostate Cancer; Epithelial Ovarrecruiting120
2026-12 est.P1/P2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06840002 A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian CancerOvarian Cancerrecruiting150
2026-12-01 est.P2K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, IncNCT05128825 A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal CancerHigh-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancerrecruiting310
2026-12-15 est.P1/P2PMV Pharmaceuticals, Inc PMVPNCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)Advanced Solid Tumor; Advanced Malignant Neoplasm; Metastatic Cancer; Metastatic Solid Tumor; Lung Crecruiting300
2026-12-26 est.P3CanariaBio Inc.NCT04498117 Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking SurgeryCarcinoma, Ovarian Epithelial; Ovarian Neoplasms; Ovarian Cancer; Ovarian Serous Adenocarcinoma; Falactive not recruiting615
2026-12-28 est.P2GlaxoSmithKlineNCT04641247 A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib StudyOvarian Neoplasms; Breast Neoplasmsrecruiting37
2026-12-30 est.P2CanariaBio Inc.NCT05335993 A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.Recurrent Ovarian Cancer; Recurrent Epithelial Cancer of Ovary; Recurrent Epithelial Ovarian Cancer;active not recruiting10
2026-12-30 est.P3Jiangsu Alphamab Biopharmaceuticals Co., LtdNCT06751485 JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian CancerOvarian Cancer; Primary Peritoneal; Fallopian Tube Cancersnot yet recruiting430
2026-12-30 est.P1/P2Astellas Pharma Global Development, Inc.NCT06792435 XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.Pancreatic Adenocarcinoma Metastatic; Lung Cancer (NSCLC); Ovarian Cancer; Colorectal Cancer Metastaactive not recruiting240
2026-12-31 est.P1/P2OncoC4, Inc.NCT04140526 Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCNon Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcactive not recruiting733
2026-12-31 est.P1/P2BicycleTx LimitedNCT04180371 Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 ExpressionAdvanced Solid Tumor Historically Known for High EphA2 Expression; Urothelial Cancer; Ovarian Canceractive not recruiting288
2026-12-31 est.P2Pfizer PFENCT04553133 PF-07104091 as a Single Agent and in Combination TherapySmall Cell Lung Cancer; Ovarian Cancer; Breast Canceractive not recruiting157
2026-12-31 est.P3Pfizer PFENCT05059522 Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are ClosingAdvanced Malignancies; NSCLC; Ovarian Cancer; Urothelial Cancer; Solid Tumorsactive not recruiting77
2026-12-31 est.P2Shanghai Jiaolian Drug Research and Development Co., LtdNCT06434610 A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.Platinum-resistant Recurrent Ovarian Cancerrecruiting90
2026-12-31 est.P2Jazz Pharmaceuticals JAZZNCT06695845 A Phase 2 Study of Zanidatamab in Patients With HER2-expressing TumorsBreast Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Cancer; Colorectal Cancer; Endomerecruiting200
2026-12-31 est.P2Beijing Biostar Pharmaceuticals Co., Ltd.NCT06730581 Utidelone Capsule Monotherapy for Patients with Advanced Solid TumorsGastric Cancer Adenocarcinoma Metastatic; Ovarian Cancer; Bile Duct Cancernot yet recruiting100
2026-12-31 est.P2Shanghai Henlius BiotechNCT06769152 A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Patients With Advanced Gynecological Malignant TumorsCervical Cancer; Ovarian Cancerrecruiting190
2026-12-31 est.P1/P2Evopoint Biosciences Inc.NCT06799637 Study of XNW28012 in Subjects With Advanced Solid Tumors Who Failed Standard TreatmentsAdvanced Solid Tumors; Pancreatic Carcinoma; Ovarian Cancer; Cervical Cancersrecruiting350
2027-01 est.P1/P2BicycleTx LimitedNCT04561362 Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced MalignanciesUrinary Bladder Neoplasm; Triple Negative Breast Neoplasms; Hormone Receptor Positive, HER2-negativeactive not recruiting329
2027-01-01 est.P1/P2Second Life TherapeuticsNCT07341737 SL-28 for Advanced Solid TumoursHead & Neck Cancer; Pancreas Carcinoma; Pancreas Cancer, Metastatic; Lung Adenocarcinoma; Lung Cancerecruiting60
2027-02 est.P1/P2Day One Biopharmaceuticals, Inc.NCT05377996 A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid TumorsTriple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Canrecruiting360
2027-02 est.P2AbbVie ABBVNCT06365853 A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High FolRecurrent Ovarian Cancer; Folate Receptor-Alpha Positiveactive not recruiting108
2027-02-17 est.P1/P2Beijing BiotechNCT07480954 Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)Epithelial Ovarian Cancer; Primary Peritoneal Carcinoma; Fallopian Tube Carcinoma; Recurrent or Refrrecruiting36

Readouts in the last 180 days

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11 est.P2AbbVie ABBVNCT05456685 Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian CancHigh Grade Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Canceractive not recruiting125
2026-10-29P2Hoffmann-La RocheNCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (FusioBreast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell,completed534
2026-09-30 est.P2Innovent Biologics (Suzhou) Co. Ltd.NCT07124793 A Study of IBI363 Combination Therapy in Participants With Advanced Solid TumorsEGFR Mutant NSCLC and Platinum Resistant Ovarian Cancernot yet recruiting60
2026-08-30P2OncoC4, Inc.NCT05446298 ONC-392 and Pembrolizumab in Platinum Resistant Ovarian CancerOvarian Cancer; High Grade Serous Adenocarcinoma of Ovary; Primary Peritoneal Carcinoma; Fallopian Tactive not recruiting58
2026-08-18P3Genmab GMABNCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian CancerPlatinum-resistant Ovarian Canceractive not recruiting584
2026-08-11P2EMD Serono Research & Development Institute, Inc.NCT06433219 Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)Ovarian Cancercompleted63
2026-08 est.P2Clinique OvoNCT06997900 Menopur And Rekovelle Combination Study Version 2.0IVF; Controlled Ovarian Simulation; Fertility Disordersrecruiting200
2026-08 est.P2Tasly Biopharmaceuticals Co., Ltd.NCT06724263 A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid TumorsRecurrent Platinum-resistant Epithelial Ovarian Cancer; Triple Negative Breast Cancer (TNBC); Cervicnot yet recruiting120
2026-08 est.P1/P2AtlasMedx, IncorporatedNCT04503265 A Trial of AMXI-5001 for Treatment in Patients With Advanced MalignanciesAdvanced Malignant Neoplasm; Breast Cancer; Ovarian Cancer; Homologous Recombination Deficiency; Prorecruiting122
2026-07-27 est.P3AstraZeneca AZNNCT04884360 D9319C00001- 1L OC Mono Global RCTOvarian Canceractive not recruiting366
2026-07-01 est.P1/P2Scancell Ltd SCNLDNCT05329532 Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal CancerTriple Negative Breast Cancer; Renal Cell Cancer; High Grade Ovarian Serous Adenocarcinoma; Squamousrecruiting168
2026-07 est.P2AbbVie ABBVNCT06682988 A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary PeritoneAdvanced High-Grade Epithelial Ovarian Cancer; Primary Peritoneal Cancer; Fallopian Tube Cancersrecruiting110
2026-06-15 est.P2/P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06211023 A Study of SHR-A1921 With or Without Carboplatin in Subjects With Ovarian CancerOvarian Cancerunknown520
2026-06-02P1/P2Sensei Biotherapeutics, Inc.NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid TumorsSolid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancreacompleted98
2026-06 est.P1/P2Volastra Therapeutics, Inc.NCT05902988 A Phase I/II Study of VLS-1488 in Subjects With Advanced CancerAdvanced Solid Tumor; High Grade Serous Adenocarcinoma of Ovary; Squamous Non-small-cell Lung Cancerrecruiting200
2026-05-31 est.P3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06394492 SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian CancerOvarian Cancerrecruiting440

Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "ovarian cancer"); readouts matched by condition text. Registry counts only; not a forecast.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.